ICPT Intercept Pharmaceuticals Inc.

65.07
+0.66  (+1%)
Previous Close 64.41
Open 64.26
Price To Book 12.14
Market Cap 2,127,553,707
Shares 32,696,384
Volume 389,362
Short Ratio
Av. Daily Volume 480,000
Stock charts supplied by TradingView

NewsSee all news

  1. Intercept Submits New Drug Application to the U.S. FDA for Obeticholic Acid in Patients with Fibrosis Due to NASH

    NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive

  2. Intercept to Present at Upcoming Investor Conference in October

    NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive

  3. Intercept Launches NASHTRUTH.com, an Online Educational Resource for People with Advanced Fibrosis Due to NASH

    New NASH survey available on NASHTRUTH.com reveals that 6 out of 10 NASH patients say there is not enough information about the disease available to them  NASHTRUTH.com provides people living with NASH with

  4. Intercept Appoints Lisa DeFrancesco as Vice President, Investor Relations

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 enrolment to be completed in 2019.
Ocaliva - Obeticholic acid (OCA) - REVERSE
NASH patients with compensated cirrhosis
Phase 2 primary endpoint met - July 31, 2017. One patient death noted but DSMB noted unlikely to be related to OCA (company unsure).
Obeticholic acid (OCA) - CONTROL
NASH patients taking statins
Approved May 27 2016. Updated U.S. label for Ocaliva anticipated by early 2018
Obeticholic acid (Ocaliva)
Primary biliary cirrhosis (PBC) - POISE
NDA filing announced September 27, 2019.
Ocaliva (Obeticholic acid (OCA)) - REGENERATE
Adult nonalcoholic steatohepatitis (NASH) patients.
Phase 2 data released July 31, 2017 - primary endpoint met. Late breaker at AASLD October 23, 2017.
Obeticholic acid (OCA) AESOP
Primary Sclerosing Cholangitis (PSC)

Latest News

  1. Intercept Submits New Drug Application to the U.S. FDA for Obeticholic Acid in Patients with Fibrosis Due to NASH

    NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive

  2. Intercept to Present at Upcoming Investor Conference in October

    NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive

  3. Intercept Launches NASHTRUTH.com, an Online Educational Resource for People with Advanced Fibrosis Due to NASH

    New NASH survey available on NASHTRUTH.com reveals that 6 out of 10 NASH patients say there is not enough information about the disease available to them  NASHTRUTH.com provides people living with NASH with

  4. Intercept Appoints Lisa DeFrancesco as Vice President, Investor Relations

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive